Bone Biologics Corporation (BBLG) - News Archive

Bone Biologics Corporation, a leading developer of orthobiologic products for spine fusion markets, has recently treated the first two patients in a pilot clinical study involving their innovative NB1 bone graft device....

Bone Biologics Corporation, a renowned developer of orthobiologic products for spine fusion markets, is making notable advancements in its NB1 product candidate for spinal fusion. The company has received approval from...

Bone Biologics Corporation Closes Registered Direct Offering and Initiates Private Placement to Accelerate GrowthBURLINGTON, Mass. - Bone Biologics Corporation (NASDAQ: BBLG), a leading developer of orthobiologic produc...

In a significant move towards advancing its orthobiologic products for the spine fusion markets, Bone Biologics Corporation (NASDAQ: BBLG) recently announced the execution of a definitive agreement for the issuance and...